Serotonin Transporter

Overview

The serotonin transporter was cloned independently by Blakely and Amara groups in 1991–92, ending a 30-year pharmacological era in which the target of tricyclic antidepressants and SSRIs was known only functionally. SERT belongs to the SLC6 neurotransmitter:sodium symporter family — 20 human members including DAT (dopamine), NET (norepinephrine), GAT1/2/3 (GABA), GlyT1/2 (glycine), and amino acid transporters. All share a conserved 12-transmembrane architecture with intracellular N- and C-termini, and all couple substrate transport to the electrochemical sodium gradient.

SERT’s clinical relevance stems from three parallel threads: pharmacology (SSRI target), genetics (5-HTTLPR polymorphism), and peripheral biology (platelet SERT). The SSRI story is straightforward: by blocking 5-HT reuptake, SSRIs raise synaptic 5-HT concentrations, ultimately producing antidepressant, anxiolytic, and OCD-reducing effects through still-incompletely understood downstream neuroadaptations. The genetic story is more complex: the 5-HTTLPR short (s) allele reduces SERT expression ~40–50%, and the landmark Caspi et al. (2003) Science paper proposed that s/s genotype increases depression risk specifically in the context of childhood adversity and stressful life events — an influential but contested gene-environment interaction that sparked a decade of replication efforts and meta-analyses, ultimately reaching mixed conclusions about effect size.

The 2016 crystal structure of human SERT by Coleman et al. was a landmark achievement: the first atomic-resolution structure of an SLC6 member from the human nervous system. The structure revealed how escitalopram simultaneously occupies both the S1 central binding site (blocking the substrate transport pathway) and the S2 vestibular site (blocking drug egress), explaining the “two-site” model of SSRI inhibition and opening structure-guided drug design for next-generation antidepressants.

Structure

Mechanism of Action — Transport Cycle and SSRI Pharmacology

  SEROTONIN REUPTAKE TRANSPORT CYCLE (alternating access model):
  ─────────────────────────────────────────────────────────────
  STATE 1 — OUTWARD-OPEN:
    Na⁺ and Cl⁻ occupy binding sites; S1 site accessible from synapse
    5-HT enters from extracellular space and binds S1 site
    (Asp98 H-bonds to 5-HT amino group; Phe341/Phe335 hydrophobic packing)
       │
       ▼
  STATE 2 — OCCLUDED:
    External and internal gates both close simultaneously
    5-HT + Na⁺ + Cl⁻ sequestered within protein core (no exchange)
       │
       ▼
  STATE 3 — INWARD-OPEN:
    Internal gate opens; 5-HT + Na⁺ + Cl⁻ released into cytoplasm
    K⁺ or H⁺ may countertransport inward→outward (resets transporter)
       │
       ▼
  STATE 4 — RESET:
    K⁺/H⁺ binding drives return to outward-open conformation
    Na⁺/K⁺-ATPase maintains the Na⁺ gradient that powers cycle

  SSRI MECHANISM (e.g., escitalopram):
  ─────────────────────────────────────────────────────────────
  SSRI enters S1 site (competitive with 5-HT transport) AND S2 vestibule
    ↓
  SERT locked in outward-facing occluded conformation
  Transport cycle cannot complete
    ↓
  Synaptic 5-HT accumulates → extended postsynaptic 5-HT receptor activation
    ↓
  Acute effect (hours): 5-HT1A somatodendritic autoreceptors hypersensitized
  → raphe neuron firing suppressed → reduced serotonin release initially
    ↓
  Chronic effect (2–4 weeks): 5-HT1A autoreceptors desensitize/downregulate
  → raphe firing normalizes → forebrain 5-HT output chronically elevated
  → antidepressant/anxiolytic effect emerges

  SERT OCCUPANCY vs. CLINICAL ONSET:
  >80% SERT blockade achieved within HOURS of first SSRI dose
  Antidepressant effect requires 2–4 WEEKS = autoreceptor desensitization lag

• SSRI binding at S1 + S2: Crystal structures of escitalopram-bound human SERT (Coleman 2016) show the fluorophenyl group packing against Phe341/Phe335 in S1 while the dimethylaminoethyl tail projects into S2, achieving a two-site trap that dramatically slows dissociation. This explains why escitalopram has higher selectivity and slower washout than earlier-generation compounds.
• The antidepressant lag: SSRIs achieve >80% SERT occupancy within 2–4 hours of first dose. Yet antidepressant effects require 2–4 weeks. The explanation: increased synaptic 5-HT initially hyperstimulates 5-HT1A somatodendritic autoreceptors on dorsal raphe neurons, suppressing their firing and partially counteracting the SSRI-induced 5-HT increase. Chronic SSRI treatment desensitises and downregulates these autoreceptors, restoring firing and enabling sustained forebrain 5-HT elevation.
• Tricyclic antidepressants (TCAs): Bind SERT S1 site (and NET to varying degrees depending on compound) but with less selectivity and more off-target effects (muscarinic, histaminergic, α1-adrenergic receptor blockade causing anticholinergic effects, sedation, orthostatic hypotension). Still used in treatment-resistant depression and for pain syndromes.
• MDMA mechanism: MDMA enters serotonergic terminals as a SERT substrate (transported in by SERT); simultaneously inhibits vesicular VMAT2 (preventing 5-HT repackaging) and drives carrier-mediated 5-HT efflux (reverse transport). This produces massive non-exocytotic 5-HT release distinct from SSRI action, causing the acute serotonergic flood and empathogenic effects. Chronic MDMA use causes oxidative damage to SERT-expressing serotonergic axon terminals, detectable as reduced SERT density on PET imaging.
• SERT trafficking regulation: PKC activation (by PMA, phorbol esters, or downstream of Gq-coupled receptors) phosphorylates Thr616 → SERT internalization via clathrin-mediated endocytosis within 30 min, reducing surface 5-HT uptake. PP2A phosphatase maintains surface SERT expression. Lipid raft/cholesterol disruption reduces SERT activity. Syntaxin 1A directly binds SERT N-terminus and attenuates transport velocity.

Physiological Roles

Pathology

Connections

References

• Blakely RD, Berson HE, Fremeau RT Jr, et al. Cloning and expression of a functional serotonin transporter from rat brain. Nature. 1991;354(6348):66–70. doi:10.1038/354066a0
• Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386–9. doi:10.1126/science.1083968
• Coleman JA, Green EM, Bhatt DL. X-ray structures and mechanism of the human serotonin transporter. Nature. 2016;532(7599):334–339. doi:10.1038/nature17629
• Murphy DL, Lesch KP. Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci. 2008;9(2):85–96. doi:10.1038/nrn2284